Considering the role of receptor tyrosine kinases (RTKs) in promoting cell growth and viability, it is not surprising that their aberrant activation plays imperative roles in the maintenance of the malignant phenotype of specific subtypes of human cancer; this observation underlies the ongoing clinical integration of tyrosine kinase inhibitors (TKIs) [4]. This evidence concerns the gene NTRK1 and cancer.